The efficacy of polymyxin B in treating stroke-associated pneumonia with carbapenem-resistant Gram-negative bacteria infections: a multicenter real-world study using propensity score matching
- PMID: 40183094
- PMCID: PMC11965127
- DOI: 10.3389/fphar.2025.1413563
The efficacy of polymyxin B in treating stroke-associated pneumonia with carbapenem-resistant Gram-negative bacteria infections: a multicenter real-world study using propensity score matching
Abstract
Objectives: Infection with Carbapenem-resistant Gram-negative bacteria (CR-GNB) poses further challenges in treating stroke-associated pneumonia (SAP) patients. This multicenter retrospective study aimed to evaluate the efficacy of polymyxin B (PMB) in CR-GNB-infected SAP patients and to identify factors that may influence its effectiveness.
Methods: From 1 September 2019, and 30 December 2022, a total of 196 CR-GNB-infected SAP patients from five hospitals in China were included in the study based on specific criteria. Demographics and clinical data were obtained from the electronic medical records. Propensity score matching (PSM) was used to minimize the effect of potential confounding variables. Univariate analysis and multivariate logistic analysis were performed to identify risk factors affecting microbial efficacy.
Results: Among the 196 SAP patients infected with CR-GNB, 24.5% received PMB combined inhalation and 75.5% received non-combined inhalation treatment. The clinical success rate was 68.9%, with 25.5% achieving microbial efficacy within 7 days and 37.8% achieving microbial cure. The 30-day all-cause mortality rate was 14.8%. The incidence of acute kidney injury was 34.7%. After adjustment by propensity score matching, the PMB combined inhalation group exhibited significantly higher microbial efficacy compared to the non-combined inhalation group (46.7% vs. 26.7%, p = 0.049). Multivariate logistic analysis identified multi-site infections and Carbapenem-resistant Pseudomonas aeruginosa infection as independent risk factors for microbial efficacy.
Conclusion: Combined inhalation of PMB demonstrated superior effectiveness in microbial clearance compared to non-combined inhalation in treating CR-GNB-infected SAP patients. We recommend aerosol combined inhalation of PMB and suggest developing personalized PMB-based regimens for individual patients to enhance treatment outcomes.
Keywords: carbapenem-resistant gram-negative bacteria; clinical efficacy; microbial efficacy; polymyxin B; stroke-associated pneumonia.
Copyright © 2025 Zhuang, Chen, Wang, Qu, Xu, Hu, Wu, Chen, Wan, Xu, Long, Luo, Zhang and Qu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.Front Med (Lausanne). 2021 Feb 9;8:620885. doi: 10.3389/fmed.2021.620885. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33634151 Free PMC article.
-
Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety.Infect Drug Resist. 2022 Mar 22;15:1205-1218. doi: 10.2147/IDR.S357746. eCollection 2022. Infect Drug Resist. 2022. PMID: 35345474 Free PMC article.
-
Early appropriate therapy with polymyxin B reduces the mortality in burn sepsis caused by carbapenem-resistant gram-negative bacteria: a retrospective analysis.Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1433-1442. doi: 10.1007/s10096-025-05119-3. Epub 2025 Apr 3. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40178717
-
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?Expert Rev Anti Infect Ther. 2023 Apr;21(4):387-429. doi: 10.1080/14787210.2023.2184346. Epub 2023 Mar 8. Expert Rev Anti Infect Ther. 2023. PMID: 36820511 Review.
-
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Front Cell Infect Microbiol. 2022 Mar 15;12:823684. doi: 10.3389/fcimb.2022.823684. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35372099 Free PMC article. Review.
Cited by
-
Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.Pharmaceutics. 2025 Aug 20;17(8):1077. doi: 10.3390/pharmaceutics17081077. Pharmaceutics. 2025. PMID: 40871096 Free PMC article. Review.
References
-
- Bellomo R., Ronco C., Kellum J. A., Mehta R. L., Palevsky P., Acute Dialysis Quality Initiative w. (2004). Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8 (4), R204–R212. 10.1186/cc2872 - DOI - PMC - PubMed
-
- Chen X., Xu J., Zhu Q., Ren Y., Zhao L. (2020). Polymyxin B resistance rates in carbapenem-resistant Pseudomonas aeruginosa isolates and a comparison between Etest(®) and broth microdilution methods of antimicrobial susceptibility testing. Exp. Ther. Med. 20 (2), 762–769. 10.3892/etm.2020.8777 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous